A robust segmental performance is likely to have benefited RSG's top line in the fourth quarter of 2024.

HubSpot is expected to record top-line growth in the fourth quarter, driven by healthy demand trends and AI focus.

MCD's fourth-quarter 2024 top line is likely to have been aided by strong digital adoption, innovative menu additions and unit expansion.

CSGP's fourth-quarter 2024 top line is likely to have reflected a robust portfolio of marketplaces, which includes Apartments.com, LoopNet and...

CROX's fourth-quarter 2024 top-line results are likely to reflect gains from solid consumer demand and strength in clogs, sandals and personalization.

IQV's top line in the fourth quarter of 2024 is expected to have benefited from the rising use of GenAI to provide crucial insights.

PEGA's fourth-quarter 2024 results are likely to benefit from increased adoption of GenAI Blueprint tool and Pega Cloud platform.

GEHC's fourth-quarter results are likely to reflect mixed segmental performance in imaging, advanced visualization solutions and patient care. Pharma...

West Pharmaceutical's overall top line in the fourth quarter of 2024 continues to benefit from revenue growth in its Proprietary Products segment.

Softness in the transportation market is likely to have hurt HWM's fourth-quarter performance. Strength in the commercial and defense aerospace...